Available Options
Size: | Quantity | ||
---|---|---|---|
10 mg | $50.00 | ||
50 mg | $175.00 |
Request Quote / Bulk / Custom Size
Product Inquiry
Size: | Quantity | ||
---|---|---|---|
10 mg | $50.00 | ||
50 mg | $175.00 |
Umifenovir (131707-23-8) is a broad-spectrum antiviral medication.1 It has shown activity against influenza A,B,and C, respiratory syncytial, SARS-CoV, adeno, parainfluenza type 5, polio, rhino, coxsackie, hanta, chikungungya, hepatitis B and C viruses.2,3 It blocks hemagglutinin-mediated membrane fusion of influenza virus particles.4 Umifenovir has recently been shown to inhibit SARS-CoV2 infection by blocking virus entry as well as release from endolysosomes during intracellular trafficking.5 It has been suggested that Umifenovir may block trimerization of the spike glycoprotein, a key step in host cell adhesion.6
References/Citations:
1) Blasing et al. (2014), Arbidol as a broad-spectrum antiviral: an update; Antiviral Res, 107 84
2) Boriskin et al. (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion; Curr. Med. Chem., 15 997
3) Brooks et al. (2012) Antiviral activity of Arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions; J. Med. Virol., 84 170
4) Leneva et al. (2009) Characteristics of Arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol; Antiviral Res., 81 132
5) Wang et al. (2020) The anti-influenza drug, arbidol, is an efficient inhibitor of SARS-CoV-2 in vitro; Cell Discov., 6 28
6) Vankadari (2020) Arbidol: A Potential Antiviral Drug for the Treatment of SARS-CoV-2 by Blocking Trimerization of the Spike Glycoprotein; Int. J. Antimicrob. Agents, 56 105998
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee
Umifenovir (131707-23-8) is a broad-spectrum antiviral medication.1 It has shown activity against influenza A,B,and C, respiratory syncytial, SARS-CoV, adeno, parainfluenza type 5, polio, rhino, coxsackie, hanta, chikungungya, hepatitis B and C viruses.2,3 It blocks hemagglutinin-mediated membrane fusion of influenza virus particles.4 Umifenovir has recently been shown to inhibit SARS-CoV2 infection by blocking virus entry as well as release from endolysosomes during intracellular trafficking.5 It has been suggested that Umifenovir may block trimerization of the spike glycoprotein, a key step in host cell adhesion.6
References/Citations:
1) Blasing et al. (2014), Arbidol as a broad-spectrum antiviral: an update; Antiviral Res, 107 84
2) Boriskin et al. (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion; Curr. Med. Chem., 15 997
3) Brooks et al. (2012) Antiviral activity of Arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions; J. Med. Virol., 84 170
4) Leneva et al. (2009) Characteristics of Arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol; Antiviral Res., 81 132
5) Wang et al. (2020) The anti-influenza drug, arbidol, is an efficient inhibitor of SARS-CoV-2 in vitro; Cell Discov., 6 28
6) Vankadari (2020) Arbidol: A Potential Antiviral Drug for the Treatment of SARS-CoV-2 by Blocking Trimerization of the Spike Glycoprotein; Int. J. Antimicrob. Agents, 56 105998
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass